Nexus gains FDA nod for generic Erythrocin

The medication is indicated in the treatment of infections caused by susceptible strains of designated organisms in certain diseases when oral administration is not possible.
Levy

Nexus Pharmaceuticals has received the Food and Drug Administration’s clearance for erythromycin lactobionate for injection, in 500mg/vial in single-dose vials.

The medication is the generic of Pfizer’s Erythrocin. 

[Read more: Nexus intros generic Quelicin]

It is indicated in the treatment of infections caused by susceptible strains of designated organisms in certain diseases when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin.

“We are very proud of the hard work of our team in gaining approval of this product,” Usman Ahmed, chief operating officer of Nexus, said. “Bringing this product to market showcases Nexus’ commitment to ending drug shortages in the U.S. and solving today’s critical healthcare challenges.”

[Read more: Nexus debuts potassium chloride in water for injection]

The generic product will be available in cartons of five single-dose vials.

X
This ad will auto-close in 10 seconds